Gadolinium based C60 fullerene-paclitaxel-ZME-018 conjugates (TDA Research/Rice University/MD Anderson)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameGadolinium based C60 fullerene-paclitaxel-ZME-018 conjugates (TDA Research/Rice University/MD Anderson)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionMicrotubule stabilizer
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTDA Research Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRice UniversityTDA Research IncThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A